Anastrozole Monotherapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Anastrozole Monotherapy, 2018, version number 3, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6358/254_v5_Anastrazole.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women.	3
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.	3
Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.	3

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
HSE (2)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole
HSE (2)	ER positive, HER2-positive	Invasive Breast Carcinoma	Anastrozole
HSE (2)	HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole
HSE (1)	ER positive	Invasive Breast Carcinoma	Anastrozole
HSE (1)	PR positive	Invasive Breast Carcinoma	Anastrozole
HSE (1)	ER positive, PR positive	Invasive Breast Carcinoma	Anastrozole